

■**Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial.**

Kataoka K, Nishiyama O, Ogura T, Mori Y, Kozu R, Arizono S, Tsuda T, Tomioka H, Tomii K, Sakamoto K, Ishimoto H, Kagajo M, Ito H, Ichikado K, Sasano H, Eda S, Arita M, Goto Y, [Hataji O](#), Fuke S, Shintani R, Hasegawa H, Ando M, Ogawa T, Shiraishi M, Watanabe F, Nishimura K, Sasaki T, Miyazaki S, Saka H, Kondoh Y; FITNESS study Collaborators. *Thorax*. 2023 Aug;78(8):784-791. doi: 10.1136/thorax-2022-219792. Epub 2023 Apr 3.

■**Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.**

Ikeda M, Okugawa S, Kashiwabara K, Moritoyo T, Kanno Y, Jubishi D, Hashimoto H, Okamoto K, Tsushima K, Uchida Y, Mitsumura T, Igari H, Tsutsumi T, Araoka H, Yatera K, Yamamoto Y, Nakamura Y, Otani A, Yamashita M, Wakimoto Y, Shinohara T, Adachi-Katayama M, Oyabu T, Kanematsu A, Harada S, Takeshita Y, Nakano Y, Miyazaki Y, Sakao S, Saito M, Ogura S, Yamasaki K, Kawasuji H, [Hataji O](#), Inoue JI, Seto Y, Moriya K. *Int J Infect Dis*. 2023 Mar;128:355-363. doi: 10.1016/j.ijid.2022.12.039. Epub 2023 Jan 4.

■**Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL).**

Miura S, Nishio M, Akamatsu H, Goto Y, Hayashi H, Gemma A, Yoshino I, Misumi T, Hata A, [Hataji O](#), Fujita K, Seike M, Yanagitani N, Nishino K, Hara S, Saito R, Mori M, Tsuda T, Iwasawa S, Nakagawa S, Mitsudomi T. *JTO Clin Res Rep*. 2023 Feb 24;4(3):100484. doi: 10.1016/j.jtocrr.2023.100484. eCollection 2023 Mar.

■**Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.**

Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, [Hataji O](#), Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. *JAMA Oncol*. 2023 Dec 21:e235258. doi: 10.1001/jamaoncol.2023.5258. Online ahead of print.

■**Risk factors for disease progression in fibrotic hypersensitivity pneumonitis.**

Fujimoto H, Yasuma T, D'Alessandro-Gabazza CN, Gabazza EC, [Hataji O](#), Kobayashi T. *Eur Respir J*. 2023 Jan 27;61(1):2201706. doi: 10.1183/13993003.01706-2022. Print 2023 Jan.

■**Development of a Communication Tool between Patients and Physicians for Recognizing COPD Exacerbations in Japan.**

Jones P, [Hataji O](#), Suzukamo Y, Crawford B, Sakai Y, Ishii T, Sato K, Sasaki E, Hashimoto K, Oga T. *COPD*. 2023 Dec;20(1):216-223. doi: 10.1080/15412555.2023.2219742.

■**Epoprostenol and Treprostinil: Differential Effects on Regulatory T-Cell Generation in Patients with Pulmonary Arterial Hypertension.**

Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, Gabazza EC, [Hataji O](#), Kobayashi T. *Am J Respir Crit Care Med*. 2023 Dec 1;208(11):1248. doi: 10.1164/rccm.202308-1347LE.

■**Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.**

[Ito A](#), [Tarukawa T](#), [Suzuki Y](#), [Sakaguchi T](#), [Ito K](#), [Fujiwara K](#), [Nishii Y](#), [Taguchi O](#), [Yasui H](#), Takao M, [Hataji O](#). *Anticancer Res*. 2023 Nov;43(11):5197-5204. doi: 10.21873/anticancer.16721.

■**Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.**

Matsuzawa R, Morise M, [Ito K](#), [Hataji O](#), Takahashi K, Koyama J, Kuwatsuka Y, Goto Y, Imaizumi K, Itani H, Yamaguchi T, Zenke Y, Oki M, Ishii M. *EClinicalMedicine*. 2023 Nov 10;66:102303. doi: 10.1016/j.eclinm.2023.102303. eCollection 2023 Dec.

■**Physical Activity Estimated by the Wearable Device in Lung Disease Patients: Exploratory Analyses of Prospective Observational Study.**

[Ito K](#), [Esumi M](#), [Esumi S](#), [Suzuki Y](#), [Sakaguchi T](#), [Fujiwara K](#), [Nishii Y](#), [Yasui H](#), [Taguchi O](#), [Hataji O](#). *J Clin Med*. 2023 Jun 30;12(13):4424. doi: 10.3390/jcm12134424.

■**Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions.**

[Nishii Y](#), [Sakaguchi T](#), [Esumi S](#), [Esumi M](#), [Nakamura Y](#), [Suzuki Y](#), [Ito K](#), [Fujiwara K](#), [Yasui H](#), [Ito A](#), [Tarukawa T](#), Tsuruga T, D'Alessandro-Gabazza CN, Yasuma T, Fujimoto H, Asano F, Gabazza EC, Kobayashi T, [Taguchi O](#), [Hataji O](#). *Sci Rep*. 2023 Sep 7;13(1):14724. doi: 10.1038/s41598-023-41726-w.

■**A case of tracheal stenosis due to anaplastic thyroid carcinoma treated using the stent-in-stent method.**

[Sakaguchi T](#), [Ohi M](#), [Nishii Y](#), [Hataji O](#). *Thorac Cancer*. 2023 Dec 27. doi: 10.1111/1759-7714.15185. Online ahead of print.

■ **Refractory response to entrectinib for ROS-1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report.**

Ito K, Nishio M, Fujiwara K, Nishii Y, Ushiro K, Yasui H, Hataji O.

Thorac Cancer. 2023 Sep;14(25):2622-2626. doi: 10.1111/1759-7714.15044. Epub 2023 Aug 6.

■ **Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.**

Sakaguchi T, Iketani A, Esumi S, Esumi M, Suzuki Y, Ito K, Fujiwara K, Nishii Y, Katsuta K, Yasui H, Taguchi O, Hataji O.

Sci Rep. 2023 Aug 23;13(1):13759. doi: 10.1038/s41598-023-40271-w.

■ **Elevated plasma and bile levels of corisin, a microbiota-derived proapoptotic peptide, in patients with severe acute cholangitis.**

Nishiwaki R, Imoto I, Oka S, Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, Toda M, Kobayashi T, Hataji O, Fujibe K, Nishikawa K, Hamaguchi T, Sugimasa N, Noji M, Ito Y, Takeuchi K, Cann I, Inoue Y, Kato T, Gabazza EC.

Gut Pathog. 2023 Nov 30;15(1):59. doi: 10.1186/s13099-023-00587-4.

■ **Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.**

Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Kijima T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Tokito T, Murakami S, Tamiya A, Yokouchi H, Watanabe S, Yamaguchi O, Morinaga R, Jodai T, Ito K, Shiraishi Y, Kogure Y, Shibaki R, Yamamoto N.

Sci Rep. 2023 Mar 6;13(1):3698. doi: 10.1038/s41598-023-30676-y.

■ **Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.**

Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Nakagawa K.

Clin Lung Cancer. 2023 Sep;24(6):519-527.e4. doi: 10.1016/j.clcc.2023.05.008. Epub 2023 Jun 3.

■ **Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).**

Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T, Yanagitani N, Mizutani H, Ninomiya T, Kajiwara T, Ito K, Miyanaga A, Arai D, Kodama H, Kobayashi K, Kaira K.

Eur J Cancer. 2023 May;184:62-72. doi: 10.1016/j.ejca.2023.01.025. Epub 2023 Feb 11.

■ **A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L).**

Wakuda K, Yamaguchi H, Kenmotsu H, Fukuda M, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K.

JTO Clin Res Rep. 2023 Oct 12;4(12):100587. doi: 10.1016/j.jtocrr.2023.100587. eCollection 2023 Dec.

■ **Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.**

Hazama D, Nakahama K, Kodama H, Miyazaki A, Azuma K, Kawashima Y, Sato Y, Ito K, Shiraishi Y, Miura K, Takahama T, Oizumi S, Namba Y, Ikeda S, Yoshioka H, Tsuya A, Yasuda Y, Negi Y, Hara A, Toda M, Tachihara M.

JTO Clin Res Rep. 2023 Nov 27;5(1):100613. doi: 10.1016/j.jtocrr.2023.100613. eCollection 2024 Jan.

■ **Value of adding ultrathin bronchoscopy to thin bronchoscopy for peripheral pulmonary lesions: A multicentre prospective study.**

Oki M, Saka H, Himeji D, Imabayashi T, Nishii Y, Ando M.

Respirology. 2023 Feb;28(2):152-158. doi: 10.1111/resp.14397. Epub 2022 Oct 26.

■ **Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study.**

Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Itani H, Endo T, Saito AM, Shibayama T, Yamamoto N, Gemma A.

JTO Clin Res Rep. 2023 Apr 6;4(6):100514. doi: 10.1016/j.jtocrr.2023.100514. eCollection 2023 Jun.